极早产儿早期低剂量氢化可的松治疗与2岁时神经发育结局的关联
该研究为PREMILOC随机临床试验的探索性次要分析,纳入2008至2014年法国21个新生儿ICU的523例极早产儿,随机接受安慰剂或氢化可的松(0.5 mg/kg每日两次用7天,随后0.5 mg/kg每日一次用3天)。2岁时共379例(93%)完成评估,氢化可的松组与安慰剂组无神经发育损害比例(73% vs 70%)、轻度损害(20% vs 18%)、中重度损害(7% vs 11%)分布无统计学显著差异(P=0.33)。全局发育商均值组间差异0.3(95%CI -2.7至3.4;P=0.83),脑瘫或其他主要神经损害发生率无显著差异。结论认为早期低剂量氢化可的松与2岁时神经发育无统计学显著差异,但需进一步随机研究提供确定性评估。
要点
- 极早产儿早期低剂量氢化可的松组与安慰剂组2岁时无神经发育损害比例分别为73%和70%,分布差异无统计学意义(P=0.33)。
- 全局发育商均值氢化可的松组91.7 vs 安慰剂组91.4,组间差异0.3(95%CI -2.7至3.4;P=0.83),未达统计学显著。
- 中重度神经发育损害发生率氢化可的松组7% vs 安慰剂组11%,组间差异无统计学意义。
- 脑瘫或其他主要神经损害发生率两组间无显著差异。
- 作者认为需进一步随机研究对极早产儿氢化可的松的神经发育安全性作出确定性评估。
适用人群与场景
- 极早产儿,来自2008至2014年法国21个新生儿ICU的PREMILOC随机临床试验。
- 随机分组按胎龄组分层。
- 共筛查1072例,523例随机分配(氢化可的松组256例,安慰剂组267例),406例存活至2岁。
处置流程与药物剂量
- 氢化可的松组:出生后给予氢化可的松0.5 mg/kg每日两次,共7天,随后0.5 mg/kg每日一次,共3天。
- 对照组:安慰剂。
研究设计与关键结果
- 研究类型:随机临床试验的探索性次要分析;样本量:523例随机分配,379例(93%)完成2岁评估(氢化可的松组194例,安慰剂组185例);21个法国新生儿ICU。
- 评估中位矫正年龄22个月(四分位距21-23个月)。
- 无神经发育损害比例:氢化可的松组73% vs 安慰剂组70%;轻度损害:20% vs 18%;中重度损害:7% vs 11%;组间分布差异无统计学意义(P=0.33)。
- 全局发育商均值:氢化可的松组91.7 vs 安慰剂组91.4;组间差异0.3(95%CI -2.7至3.4;P=0.83),未达统计学显著。
- 脑瘫或其他主要神经损害发生率两组间无显著差异。
证据类型、等级与局限
- 证据类型:随机临床试验(PREMILOC)的探索性次要分析。
- 局限:原文报告需进一步随机研究以对氢化可的松的神经发育安全性作出确定性评估。
对床旁实践的改变
- 对于极早产儿,早期低剂量氢化可的松(0.5 mg/kg每日两次用7天,随后0.5 mg/kg每日一次用3天)与2岁时神经发育损害无统计学显著差异,此结果来自探索性次要分析。
- 作者认为需进一步随机研究提供极早产儿氢化可的松神经发育安全性的确定性评估。
指南或共识出处
- PREMILOC随机临床试验(clinicaltrials.gov Identifier: NCT00623740)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Dexamethasone to prevent bronchopulmonary dysplasia in very preterm neonates was associated with adverse neurodevelopmental events. Early low-dose hydrocortisone treatment has been reported to improve survival without bronchopulmonary dysplasia but its safety with regard to neurodevelopment remains to be assessed.
OBJECTIVE: To assess whether early hydrocortisone therapy in extremely preterm infants is associated with neurodevelopmental impairment at 2 years of age.
DESIGN, SETTING, AND PARTICIPANTS: An exploratory secondary analysis of the PREMILOC (Early Low-Dose Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia in Extremely Preterm Infants) randomized clinical trial conducted between 2008 and 2014 in 21 French neonatal intensive care units. Randomization was stratified by gestational age groups. Neurodevelopmental assessments were completed from 2010 to 2016.
INTERVENTIONS: After birth, patients were randomly assigned to receive placebo or hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days).
MAIN OUTCOMES AND MEASURES: The prespecified exploratory secondary outcome of neurodevelopmental impairment was based on a standardized neurological examination and the revised Brunet-Lézine scale (global developmental quotient score and subscores; mean norm, 100 [SD, 15]). The minimal clinically important difference on the global developmental quotient was 5 points.
RESULTS: Of 1072 neonates screened, 523 were assigned to hydrocortisone (n = 256) or placebo (n = 267) and 406 survived to 2 years of age. A total of 379 patients (93%; 46% female) were evaluated (194 in the hydrocortisone group and 185 in the placebo group) at a median corrected age of 22 months (interquartile range, 21-23 months). The distribution of patients without neurodevelopmental impairment (73% in the hydrocortisone group vs 70% in the placebo group), with mild neurodevelopmental impairment (20% in the hydrocortisone group vs 18% in the placebo group), or with moderate to severe neurodevelopmental impairment (7% in the hydrocortisone group vs 11% in the placebo group) was not statistically significantly different between groups (P = .33). The mean global developmental quotient score was not statistically significantly different between groups (91.7 in the hydrocortisone group vs 91.4 in the placebo group; between-group difference, 0.3 [95% CI, -2.7 to 3.4]; P = .83). The incidence of cerebral palsy or other major neurological impairments was not significantly different between groups.
CONCLUSIONS AND RELEVANCE: In this exploratory analysis of secondary outcomes of a randomized clinical trial of extremely preterm infants, early low-dose hydrocortisone was not associated with a statistically significant difference in neurodevelopment at 2 years of age. Further randomized studies are needed to provide definitive assessment of the neurodevelopmental safety of hydrocortisone in extremely preterm infants.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00623740.
参考来源
- Baud O, Trousson C, Biran V, et al. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age. JAMA. 2017. PMID: 28384828. doi:10.1001/jama.2017.2692
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。